A Phase I/Ib Study of the PD-1 Antibody Pembrolizumab in Combination With Ibrutinib in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications B cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 13 Jan 2017 Status changed from not yet recruiting to recruiting.
- 09 Dec 2016 Planned initiation date changed from 1 Dec 2016 to 1 Jan 2017.
- 08 Nov 2016 New trial record